SGLT2 Inhibition Updates 2021 - SGLT2 Inhibition in Cardiorenal Disease
-
Part 1 | Session 3 SGLT2 Inhibitors: Evolution from Glucose Lowering to Cardiorenal Protection
-
Part 1 | Session 4 SGLT2 Inhibitors in Cardiology Indications: The Data
-
Part 1 | Session 5 SGLT2 Inhibitors in Chronic Kidney Disease: The Data
-
Part 1 | Session 6 Panel Discussion
-
Part 2 | Session 1 Place of SGLT2 Inhibitors in the Heart Failure Treatment Algorithm
-
Part 2 | Session 2 SGLT2 Inhibitors: Safety Considerations
-
Part 2 | Session 3 How to Use SGLT2 Inhibitors in Daily Practice
-
Part 2 | Session 4 Panel Discussion
-
Part 3 | Session 1 Totality of Evidence for the Cardiorenal Patient
-
Part 3 | Session 2 Discussion
-
Part 4 | Session 1 Welcome and Introduction
-
Part 4 | Session 2 KCCQ Score Overview and Discussion
-
Part 5 | Session 1 Welcome and Introduction
-
Part 5 | Session 2 SGLT2i in the Elderly and Vulnerable Patients
-
Part 5 | Session 3 Discussion
-
Part 6 | Session 1 Welcome and Introduction
-
Part 6 | Session 2 How do SGLT2 Inhibitors Bring About Cardiorenal Benefits?
-
Part 6 | Session 3 Totality of Evidence in Heart Failure
-
Part 6 | Session 4 Trial Results Coming Out Soon
-
Part 6 | Session 5 Heart Failure Guidelines
-
Part 6 | Session 6 Panel Discussion
-
Part 7 | Session 1 Welcome and Introduction
-
Part 7 | Session 3 Panel Discussion
-
Part 8 | Session 1 Welcome and Introduction
-
Part 8 | Session 2 Soloist Trial Overview
-
Part 8 | Session 3 Discussion
Organised with scientific co-chairs Stefan Anker and Andrew Coats, this event includes presentations and panel discussions with a host of international thought-leaders.
The SGLT2 Updates 2021 conference SGLT2 Inhibition in Cardiorenal Disease: Translating Evidence into Clinical Practice covers the place of SGLT2 inhibitors in the newly released guidelines of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) as well as their implementation in clinical practice.
In addition to plenary sessions and satellite symposia the conference featured a number of Meet The Expert breakout sessions discussing the implications in treatment of specific patient subgroups including patients with comorbidities. Audience questions were submitted throughout and were addressed by the panel experts.
Educational Objectives
SGLT2 Inhibition in Cardiorenal Disease
- Prepare cardiologists, nephrologists and endocrinologists to effectively manage patients with heart failure, individually and collaboratively
- Apply findings from clinical trials into clinical practice
- Describe the role of SGLT2 inhibitors in different patient subgroups, including patients with comorbidities
- Evaluate the safety and cardiorenal benefits of glucose-lowering agents
- Implement the new guidelines of the HFA of the ESC in clinical practice
Target Audience
- Cardiologists
- Nephrologists
- Endocrinologists
More from this programme
Part 1
State of the Art 1
Part 2
SGLT2 Inhibitors in Heart Failure: A Practical Approach
Part 3
Meet The Expert: Implications for Clinical Practice - Breakout 1
Part 4
Meet The Expert: Implications for Clinical Practice - Breakout 2
Part 5
Meet The Expert: Implications for Clinical Practice - Breakout 3
Part 6
State of the Art 2
Part 7
SGLT2 Inhibitors for Heart Failure: The New Standard of Care
Part 8
Meet The Expert: Implications for Clinical Practice - Breakout 4
Part 9
Meet The Expert: Implications for Clinical Practice - Breakout 5
Part 10
Meet The Expert: Implications for Clinical Practice - Breakout 6
Faculty Biographies
Stefan Anker
Professor of Cardiology
Prof Stefan D Anker is a German cardiologist born in Berlin, Germany. He studied medicine at Charité Medical School of Humboldt University Berlin, where he completed his medical degree in 1993. He later pursued research training at the National Heart & Lung Institute, Imperial College London, completing his PhD in 1998. Following his return to Germany, Prof Anker held academic and research positions at Charité Berlin and later at University Medical Center Göttingen before returning to Charité in 2017 to serve as Professor of (Tissue) Homeostasis in Cardiology & Metabolism. His work has taken him across multiple institutions and countries through long-standing international collaborations.
Academic History
Prof Anker began his medical education at Charité Medical School, graduating in 1993. He then continued postgraduate academic training in both Germany and the United Kingdom, completing his PhD at the National Heart & Lung Institute in London…
Shelley Zieroth
Director, Heart Failure and Heart Transplant Clinics
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.
She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She is co-chair of Canada’s largest annual heart failure meeting, HF Update, and Past President of the Federation of Medical Women of Canada.
Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.